Thyroid malignancy rates according to the Bethesda reporting system in Israel - A multicenter study

Madgar, Ory; Avior, Galit; Shochat, Ilia; Joshua, Ben‐Zion; Baraf, Lior; Avidor, Yuval; Khafif, Avi; Assadi, Niddal; Alon, Eran E.

doi:10.1016/j.ejso.2021.03.237

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another multicenter study in Israel included 810 patients and indicated that the malignancy rates were higher than those reported earlier. The authors suggested that doctors should use validated data for their own country in addition to published values [61].…”

Section: Discussionmentioning

confidence: 99%

Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool

et al. 2023

View full text Add to dashboard Cite

Background The preoperative diagnosis of cytologically indeterminate thyroid nodules (ITNs) is very challenging. In this study, we aim to provide an integrated risk assessment for thyroid nodules with indeterminate cytology to guide surgical decision-making, which includes results of blood tests, molecular tests, and repeat fine-needle aspiration biopsy (FNAB). Methods The study retrospectively included 265 ITNs between June 2019 and April 2022. According to our integrated risk assessment process that starts with blood testing, followed by supplementary DNA mutation detection on the first FNAB, and finally repeat FNAB, we divided the ITNs into high-risk and low-risk groups. Performance was evaluated with sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), area under the receiver operating characteristic curve (AUC), and the consistency between the risk evaluation and histological results. Results Of the 265 ITNs, 87 were included in the risk assessment process. The risk assessment had a sensitivity of 84.1%, specificity of 83.3%, PPV of 95.1%, NPV of 57.7%, and AUC of 0.837. The nodules with consistent results between the risk groups and histological outcomes, which included malignant cases in the high-risk group and benign cases in the low-risk group, accounted for 83.9% of all risk-assessed nodules. Conclusions These data suggest that the integrated risk assessment might provide proper information for surgical decision-making in patients with ITNs.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The authors suggested that doctors should use validated data for their own country in addition to published values. (43) Although the risk-assessment tool could prevent 15 out of 18 unnecessary surgeries, it also incorrectly stopped 11 out of 69 surgeries of malignant nodules. Given that 7 false-negative nodules in this study were histologically diagnosed as papillary thyroid microcarcinoma and 3 were noninvasive follicular thyroid neoplasm with papillary-like nuclear features, we recommend that active surveillance can be adopted as a treatment option for the low-risk ITNs as there are characteristic features of indolence of these subtypes, and either tumor enlargement or the novel appearance of nodal or distant metastasis is the indication for surgery.…”

Section: Discussionmentioning

confidence: 99%

Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool

Guan

Tian

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: The preoperative diagnosis of cytologically indeterminate thyroid nodules (ITNs) is very challenging. In this study, we aim to provide an integrated risk assessment for thyroid nodules with indeterminate cytology to guide surgical decision-making. Methods: The study retrospectively included 265 ITNs between June 2019 and April 2022. According to our integrated risk assessment that includes the results of blood tests, molecular tests and repeat fine-needle aspiration biopsy (FNAB), we divided the ITNs into high-risk and low-risk groups. Performance was evaluated with sensitivity, specificity, positive predictive value (PPV), negative predictive value(NPV), area under the receiver operating characteristiccurve (AUC), and the consistency between the risk evaluation and histological results. Results:Of the 265 ITNs, 87 were included in the risk assessment process. The risk assessment had a sensitivity of 84.1%, specificity of 83.3%, PPV of 95.1%, NPV of 57.7% and AUC of 0.837. The nodules with consistent results between the risk groups and histological outcomes, which included malignant cases in the high-risk group and benign cases in the low-risk group, accounted for 83.9% of all risk-assessed nodules. Conclusions: These data suggest that the integrated risk assessment might provide proper information for surgical decision-making in patients with ITNs.

show abstract

Outcomes of the Bethesda system for reporting thyroid cytopathology in community- vs. institution-performed cytology

Tessler

Cohen

Shochat

et al. 2022

American Journal of Otolaryngology

View full text Add to dashboard Cite

Thyroid malignancy rates according to the Bethesda reporting system in Israel - A multicenter study

Cited by 4 publications

References 29 publications

Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool

Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool

Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool

Outcomes of the Bethesda system for reporting thyroid cytopathology in community- vs. institution-performed cytology

Contact Info

Product

Resources

About